文献速递乳房整形与再造创面修复

局部去铁胺改善放疗后组织扩张乳房再造动物模型的皮肤血管性与组织顺应性

Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction.
PubMed 文献 · Ann Plast Surg · 2019-01-01

该研究在16只无毛大鼠的放疗后组织扩张乳房再造模型中,评估新型局部去铁胺(DFX)制剂对皮肤血管性和组织顺应性的影响。结果显示放疗降低血管密度和扩张体积,而局部DFX治疗使 irradiated 皮肤的血管指标和扩张体积恢复至与非放疗对照组相似水平。提示局部DFX可能有效治疗软组织放射性损伤。

要点

  • 放疗后皮肤血管密度和扩张体积显著低于对照。
  • 局部DFX使放疗皮肤血管指标恢复至对照水平。
  • 局部DFX使放疗后扩张体积恢复至对照水平。

核心结论

  • 在放疗后组织扩张乳房再造动物模型中,局部DFX改善皮肤血管性和组织顺应性,使血管密度和最终扩张体积与非放疗对照组相似。

研究设计与样本

  • 研究使用16只无毛大鼠,等分为4组:对照组(仅扩张器)、扩张+放疗组、扩张+DFX组、扩张+放疗+DFX组。

主要发现

  • 放疗皮肤血管性低于对照:3.81 vHPF vs 8.25 vHPF,P=0.03;0.79% VVF vs 1.53% VVF,P=0.06。
  • 放疗皮肤经局部DFX治疗后组织学血管结果与对照相似:7.94 vHPF vs 8.25 HPF,P=0.985。
  • 放疗皮肤经局部DFX治疗后微CT血管造影结果与对照相似:1.05% VVF vs 1.53% VVF,P=0.272。
  • 放疗导致扩张体积低于对照:0.72 vs 0.8 mL,P=0.04;局部DFX逆转此效应,扩张体积与对照相似:0.81 vs 0.80 mL,P=0.999。

临床怎么用

  • 局部DFX可能作为软组织放射性损伤的潜在治疗药物,但需未来研究进一步表征该新型制剂。

局限性

  • 研究为动物模型,样本量16只大鼠,结论需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Postmastectomy radiation therapy is an important component of the multimodality approach to later-stage breast cancers. Unfortunately, despite its proven survival benefits, postmastectomy radiation therapy is deleterious to the skin and soft tissue, causing increased complications and worse aesthetic outcomes after breast reconstruction.There is currently no effective pharmaceutical agent to mitigate the soft tissue fibrosis and hypovascularity associated with soft tissue radiation. We hypothesized that a novel topical formulation of deferoxamine (DFX) will result in improved cutaneous vascularity and soft tissue pliability in an animal model of irradiated tissue expander-based breast reconstruction. METHODS: This study consisted of 16 hairless rats divided into 4 equal groups: a control group (expander only), a tissue expanded and irradiated group, a tissue expanded + DFX group, and a tissue expanded/irradiated/DFX group. A novel topical formulation of DFX consisted of reconstituted drug dissolved in agents designed to enhance dermal penetrance. Vessels per high-power field (vHPF) were quantified histologically; micro-computed tomography angiography was used to assess vessel volume fraction (VVF) and vessel length density. RESULTS: Irradiated skin had less vascularity compared with control (3.81 vHPF vs 8.25 vHPF, P = 0.03; 0.79% VVF vs 1.53% VVF, P = 0.06). Treatment of irradiated skin with topical DFX reversed these effects, resulting in vascular findings similar to the control group histologically (7.94 vHPF vs 8.25 HPF, P = 0.985) and via micro-computed tomography angiography (1.05% VVF vs 1.53% VVF, P = 0.272). Similarly, radiation resulted in less volume expansion compared with controls (0.72 vs 0.8 mL, P = 0.04), whereas treatment with topical DFX reversed this effect, allowing for an expansion volume similar to the control group (0.81 vs 0.80 mL, P = 0.999). CONCLUSIONS: In an animal model of irradiated tissue expander-based breast reconstruction, treatment with topical DFX improved the cutaneous vascularity and tissue pliability, resulting in vascular density and final tissue expansion volumes similar to those found in the nonirradiated control group. Topical DFX may be an effective agent for the treatment of soft tissue radiation injury; future studies are indicated to further characterize this novel drug formulation.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Dassoulas KR, Mericli AF, Wang JS, et al. Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction. Ann Plast Surg. 2019. PMID: 30531453. doi:10.1097/SAP.0000000000001655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。